Why the study?
Do oral anticoagulants prevent arterial and pulmonary embolism in patients with dilated cardiomyopathy?
Do oral anticoagulants prevent arterial and pulmonary embolism in patients with dilated cardiomyopathy?
Oral anticoagulation appears highly effective in preventing arterial and pulmonary embolism in patients with dilated cardiomyopathy, with no major bleeding complications observed.
Answers are grounded in this paper and cite their sources.
May support oral anticoagulation to prevent embolism in dilated cardiomyopathy; leaves open confirmation by randomized trials.
The incidence of arterial embolism (AE) and pulmonary embolism (PE) during treatment with oral anticoagulants (OA) or without OA therapy was studied in 38 patients with dilated cardiomyopathy (DCMP). AE/PE occurred in 17 patients (44.7%) before initiation of OA treatment. The severity of DCMP was a risk factor for AE/PE, but not the presence of atrial fibrillation or intracardial thrombi. No AE/PE episodes occurred during the period of OA therapy. No major bleeding complications were seen, probably due to the moderate intensity of OA therapy (therapeutic range 5-15% Thrombotest [TT], 2.1-4.8 International Normalized Ratio [INR], median TT value 11%, median INR 2.6). Recurrence of AE was observed in 4 of 5 patients in whom treatment with OA had been discontinued.
No takes yet. Share an insight, caveat, or question.
Kyrle et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: